Hereditary angioedema with C1 inhibitor (C1-INH) deficit: the strength of recognition (51 cases)

AUTOR(ES)

Fragnan, N.T.M.L., Tolentino, A.L.N., Borba, G.B., Oliveira, A.C., Simões, J.A., Palma, S.M.U., Constantino-Silva, R.N., Grumach, A.S.

FONTE

Braz J Med Biol Res

DATA DE PUBLICAÇÃO

14/11/2018

RESUMO

Hereditary angioedema (HAE) is a rare autosomal dominant disease due to C1 esterase inhibitor deficiency (C1-INH). The disease is characterized by subcutaneous and submucosal edema in the absence of urticaria due to the accumulation of bradykinin. This descriptive study aimed to evaluate the clinical characteristics of patients with a confirmed diagnosis of HAE referred to our Outpatient Clinic between December 2009 and November 2017. Fifty-one patients (38 F, 13 M) with a mean age of 32 years (range: 7–70 y) were included. Family history of HAE was reported in 70% (36/51) of the cases; 33/46 patients became symptomatic by 18 years of age. The median time between onset of symptoms and diagnosis was 13 years (3 mo–50 y). The most frequent triggering factors for attacks were stress (74.4%), trauma (56.4%), and hormonal variations (56%). The main symptoms were subcutaneous edema in 93.5% (43/46) of patients, gastrointestinal symptoms in 84.8% (39/46), and obstruction in the upper airways in 34.8% (16/46). Hospitalization occurred in 65.2%, of whom 13.3% had to be transferred to the Intensive Care Unit. Prophylactic treatment was instituted in 87% (40/46) of patients, and 56.5% (26/46) required additional treatment to control attacks. Owing to our data collection over a period of 8 years, a significant number of patients were identified by this HAE reference center. Despite early recognition and prophylactic treatment, a high percentage of patients were hospitalized. HAE is still diagnosed late, reinforcing the need for more reference centers specialized in diagnosis and educational projects for health professionals.

Documentos Relacionados

• Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies.
• Avaliação de mutações no gene do inibidor de C1 esterase em pacientes com angioedema hereditário
• Long-standing angioedema with C1 esterase inhibitor deficiency associated with occult lymphoma.
• Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema
• Transinhibition of C1 inhibitor synthesis in type I hereditary angioneurotic edema.